Europäische Union - Deutsch - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Europäische Union - Deutsch - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressiva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Europäische Union - Deutsch - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotische mittel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation acute myocardial infarction, in kombination mit ass bei medizinisch behandelten patienten, für die eine thrombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. weitere informationen finden sie in abschnitt 5.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris healthcare gmbh (8009064) - injektionslösung in einer fertigspritze - 3000 i.e.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris healthcare gmbh (8009064) - injektionslösung in einer fertigspritze - 8000 i.e.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 21,7 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 43,4 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 10,85 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

viatris pharma gmbh (8183833) - atorvastatin-calcium-trihydrat (ph.eur.) - kautablette - teil 1 - kautablette; atorvastatin-calcium-trihydrat (ph.eur.) (28860) 5,425 milligramm

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - amlodipinum, valsartanum, hydrochlorothiazidum - filmtabletten - filmtablette: amlodipinum 5 mg ut amlodipini besilas 6.944 mg, valsartanum 160 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 4000, talcum, e 171, pro compresso obducto. - essentielle hypertonie - synthetika